| ORIGINAL CONTRIBUTION: CURRENT APPROACHES IN STROKE MEDICINE |
|
| Year : 2015 | Volume
: 2
| Issue : 1 | Page : 12-15 |
|
|
Significance of statins and antiplatelet molecules in hyperacute acute ischemic stroke outcome
Yunis Mayasi1, Mark Knobel1, Saef Izzy2, Kevin Kane3, Majaz Moonis1
1 Department of Neurology, University of Massachusetts, Worcester, MA, USA
2 Department of Neuro-Critical Care, Massachusetts General Hospital, Boston, MA, USA
3 Department of Biostatistics, University of Massachusetts, Worcester, MA, USA
Correspondence Address:
Prof. Majaz Moonis
Director, Stroke Services, UMass Memorial Medical Center, Worcester, Massachusetts 01655
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2349-0977.168246
|
|
|
Introduction: Ischemic stroke is a major cause of morbidity and mortality. However, the interface of various premorbid medical conditions, vascular risk factors prior, prior antithrombotic or statins medication use, and in-hospital complications in effecting outcomes is not clearly established. We attempt establishing factors associated with improved outcomes after an acute ischemic stroke (AIS). Materials and Methods: Using the prospectively collected database, University Health Consortium from 1999 to 2004, a national USA database, multivariate step-wise backward regression analysis was performed and we were able to define premorbid characteristics, and medications that affect the outcome of AIS. Results: Initial stroke severity and poststroke in-hospital complications were associated with a poor outcome, while prior antiplatelet drug use was associated with an improved outcome. Statin use demonstrated a trend toward an improved outcome. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
